Cellectis Announces Participation in Five Investor Conferences
August 26 2021 - 3:34PM
Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the
“Company”), a gene-editing platform company with clinical-stage
immuno-oncology programs using allogeneic chimeric antigen receptor
(CAR)-T cells and gene therapy programs for monogenic diseases,
today announced that management plans to participate in five
virtual investor conferences.
11th
Annual Biotech Symposium (Goldman Sachs) Date:
Tuesday, September 7, 2021Time: 8AM-6PM (GMT)
Citi’s 16th Annual
Biopharma Conference 2021Date: Thursday, September 9,
2021Time: 10:40AM ET
Wells Fargo Healthcare
Conference Date: Friday, September 10, 2021Time: 9:20AM
ET
H.C. Wainwright
23rd Annual Global Investment
Conference Date: Monday, September 13, 2021Time: 7AM
ET
Baird 2021 Global Healthcare
Conference Date: Wednesday, September 15, 2021Time: 9:05
AM ET
Live webcasts of these events and a replay of
these webcasts will be available under the “Events and Webcasts”
section on the Investor page of the of the Company’s at website:
https://www.cellectis.com/en/investors/events-and-webcasts/
About CellectisCellectis is a
gene editing company, developing first of its kind therapeutic
product candidates. Cellecties utilizes an allogeneic approach for
CAR-T immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients, and a platform to make therapeutic gene editing in
hematopeitic stem cells for various diseases. As a clinical-stage
biopharmaceutical company with over 21 years of expertise in gene
editing, Cellectis is developing life-changing product candidates
utilizing TALEN®, its gene editing technology, and PulseAgile, its
pioneering electroporation system to harness the power of the
immune system in order to treat diseases with unmet medical
needs.
As part of its commitment to a cure, Cellectis
remains dedicated to its goal of providing life-saving UCART
product candidates for multiple cancers including r/r AML), r/r
B-ALL and r/r MM. .HEAL is a new platform focusing on
hematopeitic stem cells to treat blood disorders,
immunodeficiencies and lysosomial storage diseases.
Cellectis headquarters are in Paris, France,
with locations in New York, New York and Raleigh, North Carolina.
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and
on Euronext Growth (ticker: ALCLS). For more information,
visit www.cellectis.com. Follow Cellectis on social
media: @cellectis, LinkedIn and YouTube.TALEN® is
a registered trademark owned by Cellectis.
For further information, please
contact:
Media contacts:Pascalyne
Wilson, Director, Communications, +33 7 76 99 14 33,
pascalyne.wilson@cellectis.com Margaret Gandolfo, Senior Manager,
Communications, 646-628-0300, margaret.gandolfo@cellectis.com
Sheryl Seapy, Real Chemistry, 213-262-9390,
sseapy@realchemistry.com
IR contact:Eric Dutang, Chief
Financial Officer, 646-630-1748,
eric.dutang@cellectis.com
DisclaimerThis presentation
contains “forward-looking” statements within the meaning of
applicable securities laws, including the Private Securities
Litigation Reform Act of 1995. Forward-looking statements may be
identified by words such as “ “believe,” “expect,” “plan,”
“designed to,” “foresee”, “look forward,” “will,” “could,” “would”
or the negative of these and similar expressions. These
forward-looking statements, which are based on our management’s
current expectations and assumptions and on information currently
available to management, include statements about our research and
development projects and priorities, our pre-clinical project
development efforts, the timing and progress of clinical trials
(including with respect to patient enrollment and follow-up), the
timing of our presentation of clinical data, the adequacy of our
supply of clinical vials, the timing of completion of construction
of our Raleigh, North Carolina manufacturing facility, operational
capabilities at our manufacturing facilities, the sufficiency of
cash to fund our operations. These forward-looking statements are
made in light of information currently available to us and are
subject to numerous risks and uncertainties, including with respect
to the numerous risks associated with biopharmaceutical product
candidate development as well as the duration and severity of the
COVID-19 pandemic and governmental and regulatory measures
implemented in response to the evolving situation. With respect to
our cash runway, our operating plans, including product development
plans, may change as a result of various factors, including factors
currently unknown to us. Furthermore, many other important factors,
including those described in our Annual Report on Form 20-F and the
financial report (including the management report) for the year
ended December 31, 2020 and subsequent filings Cellectis makes with
the Securities Exchange Commission from time to time, as well as
other known and unknown risks and uncertainties may adversely
affect such forward-looking statements and cause our actual
results, performance or achievements to be materially different
from those expressed or implied by the forward-looking statements.
Except as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
- 2021_08_24_ September investors conferences_FINAL[33]
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Jul 2023 to Jul 2024